SEC Form 4 · accession 0001562180-16-002010
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lars Ekman
Director
Period of report
Mar 17, 2016
Accepted (ET)
Mar 21, 2016 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $54.28 | Mar 17, 2016 | A | 15,000 | A | — | Mar 16, 2026 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The option shall vest with respect to 1/36th of the shares monthly such that the options shall be fully vested on the third anniversary of the grant date.